Julie Vose, MD, M.B.A.
Professor, Internal Medicine
Division of Oncology & Hematology
Academic Office mailing address:
UNMC Oncology/Hematology Division
986840 Nebraska Medical Center
Omaha, NE 681980-6840
Main Academic Ph. 402-559-8500
New Patient Referral Ph. 402-559-5600
University of Colorado, M.B.A. (2011)
University of Nebraska Medical Center, Resident, (1987)
University of Nebraska Medical Center, Chief Resident, (1988)
University of Nebraska Medical Center, Fellow, (1990)
South Dakota State University, BS, (1978)
University of Nebraska Medical Center, B.S. MT (ASCP), (1979)
University of Nebraska Medical Center, MD, (1984)
Research in novel therapies for Hodgkin disease, non-Hodgkin lymphoma, Multiple Myeloma, CLL
Dr Vose is the Neumann M. and Mildred E. Harris Professorial Chair and is the current Chief of the Oncology/Hematology Division in the Department of Internal Medicine at UNMC. Dr Vose received all of her medical education and training at UNMC and has been on faculty since 1990. Dr Vose is an internationally known leading expert in the treatment of patients with lymphoma. Dr Vose has served in many national and international review panels and is actively involved in various administrative positions in various local and national organizations. Dr Vose is actively involved in various novel clinical trials and is a member of the Nebraska Lymphoma Study Group. Dr Vose is the current co-program leader of the Hematologic Malignancy Program at the UNMC Eppley Cancer Center. Dr Vose has published over 300 articles in various medical journals, most of which deals with finding optimum care and treatment for patients with lymphoma. She has served on the editorial boards of various hematology and oncology journals, and serves as an expert reviewer as well.
Vose JM, Levit LA, Hurley P, Lee C, Thompson MA, Stewart T, Hofacker J, Bruinooge SS, Hayes DF, Addressing administrative and regulatory burden in cancer clinical trials: Summary of a stakeholder survey and workshop hosted by the American Society of Clinical Oncology and the Association of American Cancer Institutes; J Clin Oncol 2016; Sept: e-pub ahead of print. PMID 27601549
Horwitz SM, Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Hoppe RT, Kaminski MS, Kelsey Cr, Kim YH, Krivacic S, LaCasce AS, Lunning MA, Nadamanee A, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H, Porcu P, J Natl Compr Canc Netw 2016; 14(9): 1067-1079. PMID 27587620
Vose JM, 2016 ASCO Presidential Address: “Collective Wisdom: the future of patient-centered care and research,” J Clin Oncol 2016; 34(25): 2945-2949. PMID 27400938
Schnipper LE, Davidson NE, Wollins DS, Blayney DW, Dicker AP, Ganz PA, Hoverman JR, Langdon R, Lyman GH, Meropol NJ, Mulvey T, Newcomer L, Peppercorn J, Polite B, Raghavan D, Rossi G, Saltz L, Schrag D, Smith TJ, Yu PP, Hudis CA, Vose JM, Schilsky RL, Updating the American Society of Clinical Oncology value framework: Revisions and reflections in response to comments received, J Clin Oncol 34(24); 2925-2934: 2016. PMID 27247218
Landsburg DJ, Falkiewicz MK, Petrich AM,4, Chu BA, Behdad A, Li S, Medeiros LJ, Cassaday RD, Reddy NM, Bast MA, Vose JM, Kruczek KR, Smith SE, Patel P, Hernandez-Ilizaliturri F, Karmali R, Rajguru S, Yang DT, Maly JJ, Blum KA, Zhao W, Vanslambrouck C, Nabhan C, Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable, Br J Haematol, 2016 Jul 29, Epub ahead of print. PMID 27469075
Iqbal J, Wilcox R, Naushad H, Rohr J, Heavican TB, Wang C, Bouska A, Fu K, Chan WC, Vose JM, Genomic signatures in T-cell lymphoma: How can these improve precision in diagnosis and inform prognosis?, Blood Rev 30(2); 89-100: May, 2016. PMID 26432520
Iqbal J, Naushad H, Bi C, J, Bouska A, Rohr J, Chao W, Fu K, Chang WC, Vose JM, Genomic signatures in B-cell lymphoma: How can these improve precision in diagnosis and inform prognosis? Blood Rev; 30(2): 73-88, March, 2016. PMID 26432520.
Advani RH, Ansell SM, Lechowicz MJ, Beaven AW, Loberiza F, Carson KR, Evens AM, Foss F, Horwita S, Pro B, Pinter-Brown LC, Smith SM, Shustov AR, Savage KJ, Vose JM, A phase ii study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) alternating with pralatrexate (p) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): Final results from the T-cell consortium trial, Br J Haematol 172(4); 535-544, Feb, 2016 PMID 26627450
Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Hoppe RT, Horwitz SM, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Lunning M, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Sokol L, Swinnern LJ, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H, Diffuse large B-cell lymphoma version 1.2016, J Natl Compr Canc Netw 14(2); 196-231: Feb, 2016.
Armitage JO, Vose JM, To surveil or not to surveil, J Clin Oncol 33(34), 3983-4, Dec., 2015. PMID 26438116
Vose JM, An interview with Julie Vose: Where is oncology heading?, Future Oncol 11(20), 2803-5, Sept 2015. PMID 26358047
Evens AM, Kanakry JA, Sehn LH, Kritharis A, Feldman T, Kroll A, Gascoyne RD, Abramson JS, Petrich AM, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Adeimy C, Hemminger J, Bartlett NL, Mato A, Caimi PF, Advani RH, Klein AK, Nabhan C, Smith SM, Fabregas JC, Lossis IS, Press OW, Fenske TS, Friedberg JW, Vose JM, Blum KA, Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: Characteristics, outcomes, and prognostication among a large multicenter cohort, Am J Hematol 90(9), 778-783, Sept, 2015. PMID 26044261
Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, Lih CJ, Williams PM, Shafer AL, Gerecitano J, de Vose S, Goy A, Kenkre VP, Barr PM, Blum KA, Shustov A, Advani R, Fowler NH, Vose JM, Elstrom RL, Habermann TM, Barrientos JC, McGreivy J, Fardis M, Chang BY, Clow F, Munneke B, Moussa D, Beaupre DM, Staudt LM, Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma, Nat Med 21(8), 922-926, Aug, 2015. PMID: 26193343
Vose JM, Mantle cell lymphoma: 2015 Update on diagnosis, risk-stratification and clinical management, Am J Hematol 90(8), 739-45, Aug, 2015. PMID 26103436
Levy R, Ganjoo KN, Leonard JP, Vose JM, Flinn IW, Ambinder RF, Connors JM, Berinstein NL, Belch AR, Bartlett NL, Nichols C., Emmanouilides CE, Timmerman JM, Gregory SA, Link BK, Inwards DJ, Freedman AS, Matous JV, Robertson MJ, Kunkel LA, Ingolia DE, Gentles AJ, Liu CL. Tibshirani R, Alkizadeh AA, Denney DW Jr., Active idiotypic vaccination versus control immunotherapy for follicular lymphoma, J Clin Oncol 32(17), 1797-1803, June, 2014. PMID 24799467
Iqbal J, Wright G, Wang C, Rosenwald A, Gascoyne RD, Weisenburger DD, Greiner TC, Smith L, Gujo S, Wilcox RA, The BT, Lim ST, Tna SY, Rimsza LM, Jaffe ES, Campo E, Martinez A, Delabie J, Braziel RM, Cook JR, Tubbs RR, Ott G, Geissinger E, Gaulard P, Piccaluga PP, Pileri SA, Au WY, Nakamura S, Seto M, Berger F, de Leval L, Connors JM, Armitage JO, Vose JM, Chan WC, Staudt LM, Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma, Blood 123(19), 2915-2923, May, 2014.
William BM, Allen MS, Loberiza FR, Bociek RG, Bierman PJ, Armitage JO, Vose JM, Phase I/II study of Velcade®-BEAM (V-BEAM) and autologous hematopoietic stem cell transplantation (ASCT) for relapsed indolent non-Hodgkin's lymphoma (NHL), transformed or mantle cell lymphoma (MCL), Biol Blood Marrow Trans 20(4), 536-542, April, 2014.
Vose JM, Carter S, Burns LJ, Ayala E, Press OW, Moskowitz CH, Stadtmauer EA, Mineshi S, Ambinder R, Fenske T, Horowitz M, Fisher R, Tomblyn M, Phase III randomized study of Rituximab/Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) compared with iodine-131 Tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: Results from the BMT CTN 0401 trial, J Clin Oncol 31(13), 1662-8, May, 2013. PMID 23478060
Additional Publications at PubMed.Gov: https://www.ncbi.nlm.nih.gov/pubmed